HU208636B - Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells - Google Patents

Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells Download PDF

Info

Publication number
HU208636B
HU208636B HU9201552A HU155292A HU208636B HU 208636 B HU208636 B HU 208636B HU 9201552 A HU9201552 A HU 9201552A HU 155292 A HU155292 A HU 155292A HU 208636 B HU208636 B HU 208636B
Authority
HU
Hungary
Prior art keywords
leu
glu
asp
lys
thr
Prior art date
Application number
HU9201552A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9201552D0 (en
HUT61202A (en
Inventor
Christiaan Reutelingsperger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HU9201552D0 publication Critical patent/HU9201552D0/hu
Publication of HUT61202A publication Critical patent/HUT61202A/hu
Publication of HU208636B publication Critical patent/HU208636B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HU9201552A 1989-11-11 1990-11-08 Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells HU208636B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3937607A DE3937607A1 (de) 1989-11-11 1989-11-11 Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen

Publications (3)

Publication Number Publication Date
HU9201552D0 HU9201552D0 (en) 1992-08-28
HUT61202A HUT61202A (en) 1992-12-28
HU208636B true HU208636B (en) 1993-12-28

Family

ID=6393365

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9201552A HU208636B (en) 1989-11-11 1990-11-08 Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells

Country Status (9)

Country Link
EP (1) EP0500602B1 (fr)
JP (1) JPH05501876A (fr)
AT (1) ATE120371T1 (fr)
CA (1) CA2068312A1 (fr)
DE (2) DE3937607A1 (fr)
DK (1) DK0500602T3 (fr)
ES (1) ES2071833T3 (fr)
HU (1) HU208636B (fr)
WO (1) WO1991007187A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
ATE237366T1 (de) * 1994-01-24 2003-05-15 Neorx Corp Radioaktiv-markierte annexine
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
WO1995034315A1 (fr) * 1994-06-16 1995-12-21 Neorx Corporation Conjugues radiomarques d'annexine-galactose
CA2206274C (fr) * 1994-12-07 2009-06-30 Neorx Corporation Conjugues groupes annexine-galactose radiomarques
JPH10512852A (ja) * 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
US6509316B2 (en) 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
US6288039B1 (en) 1995-03-07 2001-09-11 George Washington University Pharmaceutical compositions methods and kits for treatment and diagnosis of breast cancer
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
EP1520588B1 (fr) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System L'utilisation d'anticorps vis-a-vis des aminophospholipides pour le traitement du cancer
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
PT1520588E (pt) 1998-07-13 2015-03-31 Univ Texas Usos de anticorpos para amino fosfolípidos para o tratamento do cancro
EP1379266B1 (fr) 2001-02-21 2007-04-18 SurroMed, Inc. Annexines modifiees et prevention de la thrombose
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem

Also Published As

Publication number Publication date
DK0500602T3 (da) 1995-07-10
CA2068312A1 (fr) 1991-05-12
ES2071833T3 (es) 1995-07-01
DE59008813D1 (de) 1995-05-04
HU9201552D0 (en) 1992-08-28
EP0500602B1 (fr) 1995-03-29
ATE120371T1 (de) 1995-04-15
HUT61202A (en) 1992-12-28
DE3937607A1 (de) 1991-05-16
JPH05501876A (ja) 1993-04-08
EP0500602A1 (fr) 1992-09-02
WO1991007187A1 (fr) 1991-05-30

Similar Documents

Publication Publication Date Title
HU208636B (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
JP7003183B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
Landowski et al. Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature protein
US4656161A (en) Increasing the enteral absorbability of heparin or heparinoids
US8440628B2 (en) Medical compositions containing ghrelin
EP0706398B1 (fr) Composition pharmaceutique contenant de l'heparine, des fragments d'heparine ou leurs derives, combines avec des esters de glycerol
US5260224A (en) Therapeutic uses of actin-binding compounds
JPH01502434A (ja) 新規インシュリン誘導体
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
PT89534B (pt) Processo para a preparacao de composicoes farmaceuticas anticoagulantes contendo como ingrediente activo proteina c ou proteina c activada combinada com heparina
JPH08245418A (ja) 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
KR101024511B1 (ko) 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제
IE60649B1 (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, and pharmaceutical agents containing these mixed crystals
JPH04503070A (ja) プラスミノーゲン活性化因子蛋白の薬学的組成物
US4510135A (en) Orally administered heparin
KR100442758B1 (ko) 조직인자응고계억제제함유혈관신생저해제
KR20140083035A (ko) 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
JPH0273022A (ja) 組織プラスミノーゲン活性化因子を用いた薬学的製剤
PT1750733E (pt) Método de administração de factor viii suíno sem domínio b
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
CA2161682A1 (fr) Composition liquide de globuline pour injections intraveineuses, procede de production correspondant et procede empechant l'augmentation des dimeres de globuline dans ladite composition
PT1372700E (pt) Soluções aquosas estáveis do factor de estimulação de colónias de macrofagos granulócitos.
JP2001064199A (ja) レシチン化スーパーオキシドジスムターゼ含有医薬組成物
Verma et al. Kinetic analysis, isolation, and characterization of hydrophilic folate-binding proteins released from chorionic villi cultured under serum-free conditions
JPH01308235A (ja) ヒト成長ホルモン経鼻剤

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee